Title : RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.

Pub. Date : 2008 Jul

PMID : 18606716






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Suppression of osteoclastogenesis through RANKL inhibition may enhance the effects of docetaxel on skeletal tumors. Docetaxel tumor necrosis factor (ligand) superfamily, member 11 Mus musculus
2 RANKL inhibition may enhance docetaxel effects by increasing tumor cell apoptosis as evident by increased active caspase-3. Docetaxel tumor necrosis factor (ligand) superfamily, member 11 Mus musculus
3 These studies show that inhibition of RANKL provides an additive benefit to docetaxel treatment in a murine model of prostate cancer bone metastasis and supports clinical evaluation of this treatment option in patients. Docetaxel tumor necrosis factor (ligand) superfamily, member 11 Mus musculus